Andrei Goga, MD PhD
UCSF Professor,
​Dept. Cell & Tissue Biology 
​and Dept. of Medicine, Heme / Onc.

Andrei Goga is a basic investigator as well as a medical oncologist whose lab is focused on studies of oncogene signaling and the identification of new therapeutic strategies to target currently undrugable oncogenes.  He received prior basic science training in the lab of Dr. Owen Witte, studying aspects of BCR-ABL oncogene signaling (PhD) and Drs. David Morgan and J. Michael Bishop studying aspects of cell cycle deregulation in MYC-driven cancers (post-doc).  

​He began his independent lab at UCSF in 2007 which is currently comprised of about 7 post-doctoral fellows, 2 graduate students, and several technicians.

Dr. Goga received prior scholar awards from the Susan Komen Foundation, the Leukemia Lymphoma Society, and a CDMRP Breast Cancer Research Program Era of Hope Award.  He is currently holds the Gazarian Presidential Endowed Chair at UCSF.

---

Selected Publications (click title to download article) 

​In vivo Reprogramming of Cancer Metabolism by MYC.
Camarda R, Williams J, Goga A.
Front Cell Dev Biol. 2017 Apr 11;5:35.

MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer.
Anderton B, Camarda R, Balakrishnan S, Balakrishnan A, Kohnz RA, Lim L, Evason KJ, Momcilovic O, Kruttwig K, Huang Q, Xu G, Nomura DK, Goga A.
EMBO Rep. 2017 Apr;18(4):569-585.

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A.
Nature Medicine 2016 Nov;22(11):1321-1329. 

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A 
Nature Medicine, 2016 Apr;22(4):427-32.

Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells.
Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY, Yaswen P, Goga A, Werb Z 
Nature, 2015 Oct 1;526(7571):131-5.

CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation.
Huskey NE, Guo T, Evason KJ, Momcilovic O, Pardo D, Creasman KJ, Judson RL, Blelloch R, Oakes SA, Hebrok M, Goga A.
Stem Cell Reports. 2015 Mar 10;4(3):374-89.

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A 
The Journal of Experimental Medicine 2012 Apr 9;209(4):679-96.

miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.
Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A
Nature Medicine, 2010 Oct;16(10):1134-40.